Clinical aspects of systemic amyloid diseases

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Amyloidosis is a protein misfolding disorder in which soluble proteins aggregate as insoluble amyloid fibrils. Protein aggregates and amyloid fibrils cause functional and structural organ damage respectively. To date, at least 24 different proteins have been recognized as causative agents of amyloid diseases, localized or systemic. The two most common forms of systemic amyloidosis are light-chain (AL) amyloidosis and reactive AA amyloidosis due to chronic inflammatory diseases. β2-microglobulin amyloidosis is a common complication associated with long-term hemodialysis. Hereditary systemic amyloidoses are a group of autosomal dominant disorders caused by mutations in the genes of several plasma proteins. Heterogeneity in clinical presentation, pattern of amyloid-related organ toxicity and rate of disease progression is observed among systemic amyloidoses. In particular, β2- microglobulin presents unique clinical features compared to the other systemic forms. The phenotypic features of hereditary systemic amyloidoses may instead overlap those of the two more common forms of acquired amyloidoses mentioned above and therefore a correct diagnosis can not rely only on clinical grounds. Unequivocal identification of the deposited protein is essential in order to avoid misdiagnosis and inappropriate treatment. Amyloid deposits can be reabsorbed and organ dysfunction reversed if the concentration of the amyloidogenic protein is reduced or zeroed. At present, the most effective approach to treatment of the systemic amyloidoses involves shutting down, or substantially reducing the synthesis of the amyloid precursor, or, as in the case of β2-microglobulin, promoting its clearance.

Original languageEnglish
Pages (from-to)11-22
Number of pages12
JournalBiochimica et Biophysica Acta - Proteins and Proteomics
Volume1753
Issue number1
DOIs
Publication statusPublished - Nov 10 2005

Fingerprint

Amyloidosis
Amyloid
Familial Amyloidosis
Amyloidogenic Proteins
Proteins
Proteostasis Deficiencies
Toxicity
Blood Proteins
Amyloid Plaques
Deposits
Genes
Diagnostic Errors
Renal Dialysis
Disease Progression
Chronic Disease
Light
Mutation
Therapeutics

Keywords

  • β- microglobulin
  • Chemotherapy
  • Chronic inflammation
  • Hereditary amyloidosis
  • Immunoglobulin light-chain
  • Transplantation

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Genetics

Cite this

Clinical aspects of systemic amyloid diseases. / Obici, Laura; Perfetti, Vittorio; Palladini, Giovanni; Moratti, Remigio; Merlini, Giampaolo.

In: Biochimica et Biophysica Acta - Proteins and Proteomics, Vol. 1753, No. 1, 10.11.2005, p. 11-22.

Research output: Contribution to journalArticle

@article{f30f1199025d4adc930e01380e0296b5,
title = "Clinical aspects of systemic amyloid diseases",
abstract = "Amyloidosis is a protein misfolding disorder in which soluble proteins aggregate as insoluble amyloid fibrils. Protein aggregates and amyloid fibrils cause functional and structural organ damage respectively. To date, at least 24 different proteins have been recognized as causative agents of amyloid diseases, localized or systemic. The two most common forms of systemic amyloidosis are light-chain (AL) amyloidosis and reactive AA amyloidosis due to chronic inflammatory diseases. β2-microglobulin amyloidosis is a common complication associated with long-term hemodialysis. Hereditary systemic amyloidoses are a group of autosomal dominant disorders caused by mutations in the genes of several plasma proteins. Heterogeneity in clinical presentation, pattern of amyloid-related organ toxicity and rate of disease progression is observed among systemic amyloidoses. In particular, β2- microglobulin presents unique clinical features compared to the other systemic forms. The phenotypic features of hereditary systemic amyloidoses may instead overlap those of the two more common forms of acquired amyloidoses mentioned above and therefore a correct diagnosis can not rely only on clinical grounds. Unequivocal identification of the deposited protein is essential in order to avoid misdiagnosis and inappropriate treatment. Amyloid deposits can be reabsorbed and organ dysfunction reversed if the concentration of the amyloidogenic protein is reduced or zeroed. At present, the most effective approach to treatment of the systemic amyloidoses involves shutting down, or substantially reducing the synthesis of the amyloid precursor, or, as in the case of β2-microglobulin, promoting its clearance.",
keywords = "β- microglobulin, Chemotherapy, Chronic inflammation, Hereditary amyloidosis, Immunoglobulin light-chain, Transplantation",
author = "Laura Obici and Vittorio Perfetti and Giovanni Palladini and Remigio Moratti and Giampaolo Merlini",
year = "2005",
month = "11",
day = "10",
doi = "10.1016/j.bbapap.2005.08.014",
language = "English",
volume = "1753",
pages = "11--22",
journal = "Biochimica et Biophysica Acta - Proteins and Proteomics",
issn = "1570-9639",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Clinical aspects of systemic amyloid diseases

AU - Obici, Laura

AU - Perfetti, Vittorio

AU - Palladini, Giovanni

AU - Moratti, Remigio

AU - Merlini, Giampaolo

PY - 2005/11/10

Y1 - 2005/11/10

N2 - Amyloidosis is a protein misfolding disorder in which soluble proteins aggregate as insoluble amyloid fibrils. Protein aggregates and amyloid fibrils cause functional and structural organ damage respectively. To date, at least 24 different proteins have been recognized as causative agents of amyloid diseases, localized or systemic. The two most common forms of systemic amyloidosis are light-chain (AL) amyloidosis and reactive AA amyloidosis due to chronic inflammatory diseases. β2-microglobulin amyloidosis is a common complication associated with long-term hemodialysis. Hereditary systemic amyloidoses are a group of autosomal dominant disorders caused by mutations in the genes of several plasma proteins. Heterogeneity in clinical presentation, pattern of amyloid-related organ toxicity and rate of disease progression is observed among systemic amyloidoses. In particular, β2- microglobulin presents unique clinical features compared to the other systemic forms. The phenotypic features of hereditary systemic amyloidoses may instead overlap those of the two more common forms of acquired amyloidoses mentioned above and therefore a correct diagnosis can not rely only on clinical grounds. Unequivocal identification of the deposited protein is essential in order to avoid misdiagnosis and inappropriate treatment. Amyloid deposits can be reabsorbed and organ dysfunction reversed if the concentration of the amyloidogenic protein is reduced or zeroed. At present, the most effective approach to treatment of the systemic amyloidoses involves shutting down, or substantially reducing the synthesis of the amyloid precursor, or, as in the case of β2-microglobulin, promoting its clearance.

AB - Amyloidosis is a protein misfolding disorder in which soluble proteins aggregate as insoluble amyloid fibrils. Protein aggregates and amyloid fibrils cause functional and structural organ damage respectively. To date, at least 24 different proteins have been recognized as causative agents of amyloid diseases, localized or systemic. The two most common forms of systemic amyloidosis are light-chain (AL) amyloidosis and reactive AA amyloidosis due to chronic inflammatory diseases. β2-microglobulin amyloidosis is a common complication associated with long-term hemodialysis. Hereditary systemic amyloidoses are a group of autosomal dominant disorders caused by mutations in the genes of several plasma proteins. Heterogeneity in clinical presentation, pattern of amyloid-related organ toxicity and rate of disease progression is observed among systemic amyloidoses. In particular, β2- microglobulin presents unique clinical features compared to the other systemic forms. The phenotypic features of hereditary systemic amyloidoses may instead overlap those of the two more common forms of acquired amyloidoses mentioned above and therefore a correct diagnosis can not rely only on clinical grounds. Unequivocal identification of the deposited protein is essential in order to avoid misdiagnosis and inappropriate treatment. Amyloid deposits can be reabsorbed and organ dysfunction reversed if the concentration of the amyloidogenic protein is reduced or zeroed. At present, the most effective approach to treatment of the systemic amyloidoses involves shutting down, or substantially reducing the synthesis of the amyloid precursor, or, as in the case of β2-microglobulin, promoting its clearance.

KW - β- microglobulin

KW - Chemotherapy

KW - Chronic inflammation

KW - Hereditary amyloidosis

KW - Immunoglobulin light-chain

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=27744561904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744561904&partnerID=8YFLogxK

U2 - 10.1016/j.bbapap.2005.08.014

DO - 10.1016/j.bbapap.2005.08.014

M3 - Article

VL - 1753

SP - 11

EP - 22

JO - Biochimica et Biophysica Acta - Proteins and Proteomics

JF - Biochimica et Biophysica Acta - Proteins and Proteomics

SN - 1570-9639

IS - 1

ER -